Nfl Biosciences SAS
PAR:ALNFL
Nfl Biosciences SAS
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 3 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 3 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
